A trial-derived score explores differences in supplement benefit
Among participants without cardiovascular disease, a new score separated groups with different coronary heart disease results for omega-3 supplements versus placebo. The score needs testing in another trial.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Expected supplement benefit appeared to vary among participants without cardiovascular disease. Above the score threshold, coronary heart disease risk was lower with omega-3 than with placebo; below it, risks were numerically similar. The score remains exploratory and needs testing in another randomized trial before its predictions can be considered established.
Transfer to survey data does not replace testing in a new randomized trial. The abstract reports no confidence intervals for the score-defined risk comparisons.
What researchers found
Observed risk over five years
For scores ≥4: 2.5% with omega-3 versus 3.2% with placebo. Confidence intervals were not reported.
What informed the score
The score combined characteristics recorded before treatment. Diabetes, race, hypertension, sex and fish intake contributed most. Their contributions helped predict variation in treatment effects; they do not establish independent reasons for benefit.
What happened below the threshold
Below the score threshold, coronary heart disease risk was 1.4% with the supplement and 1.3% with placebo. These numbers do not establish equal effects or show that supplementation caused harm.
The original publication
Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL.
Hamaya R, Cook NR, Sesso HD et al.
Eur J Epidemiol · 2025
- PubMed ID
- 40569483
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.